Drug Trial Radar · NCT06747416
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 2, 2025
Primary completion
Sep 2, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Suzhou Alphamab Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and efficacy of KN057 in adult patients with severe Hemophilia A (coagulation factor FVIII activity \<1%) or moderate-to-severe Hemophilia B (FIX activity ≤2%). Participants will be administered subcutaneously with KN057 once a week for 20 weeks. KN057 works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly subcutaneous administration provides better convenience and compliance.
Conditions
- Hemophilia a and B
Interventions
KN057Drug
KN057 will be administered subcutaneously once a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent adverse events(TEAEs)Time frame: Week 0 up to Week 26
- Number of participants with abnormal laboratory findings in HematologyTime frame: Week 0 up to Week 26
- Number of participants with abnormal laboratory findings in Coagulation FunctionTime frame: Week 0 up to Week 26
- Number of participants with abnormal laboratory findings in Blood BiochemistryTime frame: Week 0 up to Week 26
- Number of participants with clinically significant changes in 12-lead electrocardiogramsTime frame: Week 0 up to Week 26
- Number of participants with clinically significant changes in vital signsTime frame: Week 0 up to Week 26
- Number of participants with clinically significant changes in physical examination FindingsTime frame: Week 0 up to Week 26
- Incidence and severity of injection site reactionTime frame: Week 0 up to Week 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.